000138738 001__ 138738
000138738 005__ 20240321220506.0
000138738 0247_ $$2doi$$a10.1016/j.neuron.2016.05.018
000138738 0247_ $$2pmid$$apmid:27292537
000138738 0247_ $$2ISSN$$a0896-6273
000138738 0247_ $$2ISSN$$a1097-4199
000138738 0247_ $$2altmetric$$aaltmetric:8613690
000138738 037__ $$aDZNE-2020-05060
000138738 041__ $$aEnglish
000138738 082__ $$a610
000138738 1001_ $$0P:(DE-2719)2810940$$aBacioglu, Mehtap$$b0$$eFirst author$$udzne
000138738 245__ $$aNeurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases.
000138738 260__ $$aNew York, NY$$bElsevier$$c2016
000138738 264_1 $$2Crossref$$3print$$bElsevier BV$$c2016-07-01
000138738 3367_ $$2DRIVER$$aarticle
000138738 3367_ $$2DataCite$$aOutput Types/Journal article
000138738 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710344685_30566
000138738 3367_ $$2BibTeX$$aARTICLE
000138738 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000138738 3367_ $$00$$2EndNote$$aJournal Article
000138738 520__ $$aA majority of current disease-modifying therapeutic approaches for age-related neurodegenerative diseases target their characteristic proteopathic lesions (α-synuclein, Tau, Aβ). To monitor such treatments, fluid biomarkers reflecting the underlying disease process are crucial. We found robust increases of neurofilament light chain (NfL) in CSF and blood in murine models of α-synucleinopathies, tauopathy, and β-amyloidosis. Blood and CSF NfL levels were strongly correlated, and NfL increases coincided with the onset and progression of the corresponding proteopathic lesions in brain. Experimental induction of α-synuclein lesions increased CSF and blood NfL levels, while blocking Aβ lesions attenuated the NfL increase. Consistently, we also found NfL increases in CSF and blood of human α-synucleinopathies, tauopathies, and Alzheimer's disease. Our results suggest that CSF and particularly blood NfL can serve as a reliable and easily accessible biomarker to monitor disease progression and treatment response in mouse models and potentially in human proteopathic neurodegenerative diseases.
000138738 536__ $$0G:(DE-HGF)POF3-342$$a342 - Disease Mechanisms and Model Systems (POF3-342)$$cPOF3-342$$fPOF III$$x0
000138738 536__ $$0G:(DE-HGF)POF3-345$$a345 - Population Studies and Genetics (POF3-345)$$cPOF3-345$$fPOF III$$x1
000138738 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x2
000138738 542__ $$2Crossref$$i2016-07-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000138738 542__ $$2Crossref$$i2017-07-06$$uhttps://www.elsevier.com/open-access/userlicense/1.0/
000138738 588__ $$aDataset connected to CrossRef, PubMed,
000138738 650_7 $$2NLM Chemicals$$aBiomarkers
000138738 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000138738 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000138738 650_2 $$2MeSH$$aAnimals
000138738 650_2 $$2MeSH$$aAxons: metabolism
000138738 650_2 $$2MeSH$$aBiomarkers: blood
000138738 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000138738 650_2 $$2MeSH$$aBrain: metabolism
000138738 650_2 $$2MeSH$$aBrain: pathology
000138738 650_2 $$2MeSH$$aDisease Progression
000138738 650_2 $$2MeSH$$aIntermediate Filaments: metabolism
000138738 650_2 $$2MeSH$$aMice, Inbred C57BL
000138738 650_2 $$2MeSH$$aMice, Transgenic
000138738 650_2 $$2MeSH$$aNeurodegenerative Diseases: diagnosis
000138738 650_2 $$2MeSH$$aNeurodegenerative Diseases: metabolism
000138738 650_2 $$2MeSH$$aNeurodegenerative Diseases: pathology
000138738 650_2 $$2MeSH$$aNeurofilament Proteins: blood
000138738 650_2 $$2MeSH$$aNeurofilament Proteins: cerebrospinal fluid
000138738 650_2 $$2MeSH$$aalpha-Synuclein: metabolism
000138738 7001_ $$0P:(DE-2719)9000196$$aMaia, Luis F$$b1$$udzne
000138738 7001_ $$0P:(DE-2719)2811828$$aPreische, Oliver$$b2$$udzne
000138738 7001_ $$0P:(DE-2719)2811018$$aSchelle, Juliane$$b3$$udzne
000138738 7001_ $$0P:(DE-2719)2812177$$aApel, Anja$$b4$$udzne
000138738 7001_ $$0P:(DE-2719)9000387$$aKaeser, Stephan A$$b5$$udzne
000138738 7001_ $$0P:(DE-2719)9000294$$aSchweighauser, Manuel$$b6$$udzne
000138738 7001_ $$0P:(DE-2719)2811141$$aEninger, Timo$$b7$$udzne
000138738 7001_ $$0P:(DE-2719)2810762$$aLambert, Marius$$b8$$udzne
000138738 7001_ $$0P:(DE-2719)9000943$$aPilotto, Andrea$$b9$$udzne
000138738 7001_ $$0P:(DE-HGF)0$$aShimshek, Derya R$$b10
000138738 7001_ $$0P:(DE-HGF)0$$aNeumann, Ulf$$b11
000138738 7001_ $$0P:(DE-2719)2810803$$aKahle, Philipp J$$b12$$udzne
000138738 7001_ $$0P:(DE-2719)9000301$$aStaufenbiel, Matthias$$b13$$udzne
000138738 7001_ $$0P:(DE-2719)2810592$$aNeumann, Manuela$$b14$$udzne
000138738 7001_ $$0P:(DE-2719)2810915$$aMaetzler, Walter$$b15$$udzne
000138738 7001_ $$0P:(DE-HGF)0$$aKuhle, Jens$$b16$$eCorresponding author
000138738 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b17$$eLast author$$udzne
000138738 77318 $$2Crossref$$3journal-article$$a10.1016/j.neuron.2016.05.018$$b : Elsevier BV, 2016-07-01$$n1$$p56-66$$tNeuron$$v91$$x0896-6273$$y2016
000138738 773__ $$0PERI:(DE-600)2001944-0$$a10.1016/j.neuron.2016.05.018$$gVol. 91, no. 1, p. 56 - 66$$n1$$p56-66$$q91:1<56 - 66$$tNeuron$$v91$$x0896-6273$$y2016
000138738 8564_ $$uhttps://pub.dzne.de/record/138738/files/DZNE-2020-05060_Restricted.pdf
000138738 8564_ $$uhttps://pub.dzne.de/record/138738/files/DZNE-2020-05060_Restricted.pdf?subformat=pdfa$$xpdfa
000138738 909CO $$ooai:pub.dzne.de:138738$$pVDB
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810940$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000196$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811828$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811018$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812177$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000387$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000294$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811141$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810762$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000943$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810803$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000301$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810592$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810915$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000138738 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b17$$kDZNE
000138738 9131_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000138738 9131_ $$0G:(DE-HGF)POF3-345$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vPopulation Studies and Genetics$$x1
000138738 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x2
000138738 9141_ $$y2016
000138738 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000138738 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000138738 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000138738 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURON : 2017
000138738 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000138738 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000138738 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000138738 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000138738 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000138738 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000138738 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000138738 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000138738 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000138738 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEURON : 2017
000138738 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x0
000138738 9201_ $$0I:(DE-2719)1210000-4$$kAG Kahle$$lFunctional Neurogenetics$$x1
000138738 9201_ $$0I:(DE-2719)5000056$$kExt UKT-Trend$$lExt UKT TREND Studie$$x2
000138738 9201_ $$0I:(DE-2719)1210003$$kAG Neumann$$lMolecular Neuropathology of Neurodegenerative Diseases$$x3
000138738 9201_ $$0I:(DE-2719)5000024$$kAG Maetzler$$lFunctional Neurogeriatrics$$x4
000138738 980__ $$ajournal
000138738 980__ $$aVDB
000138738 980__ $$aI:(DE-2719)1210001
000138738 980__ $$aI:(DE-2719)1210000-4
000138738 980__ $$aI:(DE-2719)5000056
000138738 980__ $$aI:(DE-2719)1210003
000138738 980__ $$aI:(DE-2719)5000024
000138738 980__ $$aUNRESTRICTED